Physician profile
Mahealani E Roach
NPI 1649730292
$8,711.70
in general payments reported to CMS, 2019-2025
46 companies · $1,735 in 2025
The $1,735 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,942 · 2022: $1,799 · 2023: $1,731 · 2024: $1,504 · 2025: $1,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,970.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,893.58 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $941.49 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $764.30 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $661.08 | 2021-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $645.64 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $421.76 | 2022-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $304.00 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceutical Holding Company Ltd. | $282.90 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $241.77 | 2021 | |
| Corium, LLC | $238.26 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $213.15 | 2021-2025 | Trintellix |
| Esperion Therapeutics, INC. | $190.40 | 2021-2022 | |
| Eisai INC. | $186.85 | 2021-2025 | |
| Amarin Pharma, INC. | $164.81 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $158.01 | 2021-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahealani Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.